5αDH-DOC (5α-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer

Motohide Uemura, Seijiro Honma, Suyoun Chung, Ryo Takata, Mutsuo Furihata, Kazuo Nishimura, Norio Nonomura, Yasutomo Nasu, Tsuneharu Miki, Taro Shuin, Tomoaki Fujioka, Akihiko Okuyama, Yusuke Nakamura, Hidewaki Nakagawa

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Prostate cancer often relapses during androgen-depletion therapy, even under the castration condition in which circulating androgens are drastically reduced. High expressions of androgen receptor (AR) and genes involved in androgen metabolism indicate a continued role for AR in castration-resistant prostate cancers (CRPCs). There is increasing evidence that some amounts of 5α-dihydrotestosterone (DHT) and other androgens are present sufficiently to activate AR within CRPC tissues, and enzymes involved in the androgen and steroid metabolism, such as 5α-steroid reductases, are activated in CRPCs. In this report, we screened eight natural 5αDH-steroids to search for novel products of 5α-steroid reductases, and identified 11-deoxycorticosterone (DOC) as a novel substrate for 5α-steroid reductases in CRPCs. 11-Deoxycorticosterone (DOC) and 5α-dihydro-deoxycorticosterone (5αDH-DOC) could promote prostate cancer cell proliferation through AR activation, and type 1 5α-steroid reductase (SRD5A1) could convert from DOC to 5αDH-DOC. Sensitive liquid chromatography-tandem mass spectrometric analysis detected 5αDH-DOC in some clinical CRPC tissues. These findings implicated that under an extremely low level of DHT, 5αDH-DOC and other products of 5α-steroid reductases within CRPC tissues might activate the AR pathway for prostate cancer cell proliferation and survival under castration. (Cancer Sci 2010).

Original languageEnglish
Pages (from-to)1897-1904
Number of pages8
JournalCancer Science
Volume101
Issue number8
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Desoxycorticosterone
Castration
Androgen Receptors
Prostatic Neoplasms
Steroids
Androgens
Oxidoreductases
Dihydrotestosterone
Cell Proliferation
Liquid Chromatography
Cell Survival
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Uemura, M., Honma, S., Chung, S., Takata, R., Furihata, M., Nishimura, K., ... Nakagawa, H. (2010). 5αDH-DOC (5α-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer. Cancer Science, 101(8), 1897-1904. https://doi.org/10.1111/j.1349-7006.2010.01620.x

5αDH-DOC (5α-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer. / Uemura, Motohide; Honma, Seijiro; Chung, Suyoun; Takata, Ryo; Furihata, Mutsuo; Nishimura, Kazuo; Nonomura, Norio; Nasu, Yasutomo; Miki, Tsuneharu; Shuin, Taro; Fujioka, Tomoaki; Okuyama, Akihiko; Nakamura, Yusuke; Nakagawa, Hidewaki.

In: Cancer Science, Vol. 101, No. 8, 08.2010, p. 1897-1904.

Research output: Contribution to journalArticle

Uemura, M, Honma, S, Chung, S, Takata, R, Furihata, M, Nishimura, K, Nonomura, N, Nasu, Y, Miki, T, Shuin, T, Fujioka, T, Okuyama, A, Nakamura, Y & Nakagawa, H 2010, '5αDH-DOC (5α-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer', Cancer Science, vol. 101, no. 8, pp. 1897-1904. https://doi.org/10.1111/j.1349-7006.2010.01620.x
Uemura, Motohide ; Honma, Seijiro ; Chung, Suyoun ; Takata, Ryo ; Furihata, Mutsuo ; Nishimura, Kazuo ; Nonomura, Norio ; Nasu, Yasutomo ; Miki, Tsuneharu ; Shuin, Taro ; Fujioka, Tomoaki ; Okuyama, Akihiko ; Nakamura, Yusuke ; Nakagawa, Hidewaki. / 5αDH-DOC (5α-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer. In: Cancer Science. 2010 ; Vol. 101, No. 8. pp. 1897-1904.
@article{d10cf1876bc14a25a51ba48007d1128f,
title = "5αDH-DOC (5α-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer",
abstract = "Prostate cancer often relapses during androgen-depletion therapy, even under the castration condition in which circulating androgens are drastically reduced. High expressions of androgen receptor (AR) and genes involved in androgen metabolism indicate a continued role for AR in castration-resistant prostate cancers (CRPCs). There is increasing evidence that some amounts of 5α-dihydrotestosterone (DHT) and other androgens are present sufficiently to activate AR within CRPC tissues, and enzymes involved in the androgen and steroid metabolism, such as 5α-steroid reductases, are activated in CRPCs. In this report, we screened eight natural 5αDH-steroids to search for novel products of 5α-steroid reductases, and identified 11-deoxycorticosterone (DOC) as a novel substrate for 5α-steroid reductases in CRPCs. 11-Deoxycorticosterone (DOC) and 5α-dihydro-deoxycorticosterone (5αDH-DOC) could promote prostate cancer cell proliferation through AR activation, and type 1 5α-steroid reductase (SRD5A1) could convert from DOC to 5αDH-DOC. Sensitive liquid chromatography-tandem mass spectrometric analysis detected 5αDH-DOC in some clinical CRPC tissues. These findings implicated that under an extremely low level of DHT, 5αDH-DOC and other products of 5α-steroid reductases within CRPC tissues might activate the AR pathway for prostate cancer cell proliferation and survival under castration. (Cancer Sci 2010).",
author = "Motohide Uemura and Seijiro Honma and Suyoun Chung and Ryo Takata and Mutsuo Furihata and Kazuo Nishimura and Norio Nonomura and Yasutomo Nasu and Tsuneharu Miki and Taro Shuin and Tomoaki Fujioka and Akihiko Okuyama and Yusuke Nakamura and Hidewaki Nakagawa",
year = "2010",
month = "8",
doi = "10.1111/j.1349-7006.2010.01620.x",
language = "English",
volume = "101",
pages = "1897--1904",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - 5αDH-DOC (5α-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer

AU - Uemura, Motohide

AU - Honma, Seijiro

AU - Chung, Suyoun

AU - Takata, Ryo

AU - Furihata, Mutsuo

AU - Nishimura, Kazuo

AU - Nonomura, Norio

AU - Nasu, Yasutomo

AU - Miki, Tsuneharu

AU - Shuin, Taro

AU - Fujioka, Tomoaki

AU - Okuyama, Akihiko

AU - Nakamura, Yusuke

AU - Nakagawa, Hidewaki

PY - 2010/8

Y1 - 2010/8

N2 - Prostate cancer often relapses during androgen-depletion therapy, even under the castration condition in which circulating androgens are drastically reduced. High expressions of androgen receptor (AR) and genes involved in androgen metabolism indicate a continued role for AR in castration-resistant prostate cancers (CRPCs). There is increasing evidence that some amounts of 5α-dihydrotestosterone (DHT) and other androgens are present sufficiently to activate AR within CRPC tissues, and enzymes involved in the androgen and steroid metabolism, such as 5α-steroid reductases, are activated in CRPCs. In this report, we screened eight natural 5αDH-steroids to search for novel products of 5α-steroid reductases, and identified 11-deoxycorticosterone (DOC) as a novel substrate for 5α-steroid reductases in CRPCs. 11-Deoxycorticosterone (DOC) and 5α-dihydro-deoxycorticosterone (5αDH-DOC) could promote prostate cancer cell proliferation through AR activation, and type 1 5α-steroid reductase (SRD5A1) could convert from DOC to 5αDH-DOC. Sensitive liquid chromatography-tandem mass spectrometric analysis detected 5αDH-DOC in some clinical CRPC tissues. These findings implicated that under an extremely low level of DHT, 5αDH-DOC and other products of 5α-steroid reductases within CRPC tissues might activate the AR pathway for prostate cancer cell proliferation and survival under castration. (Cancer Sci 2010).

AB - Prostate cancer often relapses during androgen-depletion therapy, even under the castration condition in which circulating androgens are drastically reduced. High expressions of androgen receptor (AR) and genes involved in androgen metabolism indicate a continued role for AR in castration-resistant prostate cancers (CRPCs). There is increasing evidence that some amounts of 5α-dihydrotestosterone (DHT) and other androgens are present sufficiently to activate AR within CRPC tissues, and enzymes involved in the androgen and steroid metabolism, such as 5α-steroid reductases, are activated in CRPCs. In this report, we screened eight natural 5αDH-steroids to search for novel products of 5α-steroid reductases, and identified 11-deoxycorticosterone (DOC) as a novel substrate for 5α-steroid reductases in CRPCs. 11-Deoxycorticosterone (DOC) and 5α-dihydro-deoxycorticosterone (5αDH-DOC) could promote prostate cancer cell proliferation through AR activation, and type 1 5α-steroid reductase (SRD5A1) could convert from DOC to 5αDH-DOC. Sensitive liquid chromatography-tandem mass spectrometric analysis detected 5αDH-DOC in some clinical CRPC tissues. These findings implicated that under an extremely low level of DHT, 5αDH-DOC and other products of 5α-steroid reductases within CRPC tissues might activate the AR pathway for prostate cancer cell proliferation and survival under castration. (Cancer Sci 2010).

UR - http://www.scopus.com/inward/record.url?scp=77954847434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954847434&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2010.01620.x

DO - 10.1111/j.1349-7006.2010.01620.x

M3 - Article

VL - 101

SP - 1897

EP - 1904

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 8

ER -